CCO Infectious Disease Podcast

Beyond CMV Prevention

Episode Summary

Listen to Raymund Razonable, MD, discuss CMV management strategies beyond primary prophylaxis in solid organ transplantation recipients including considerations for secondary prophylaxis and approaches to CMV treatment.

Episode Notes

In this episode, Raymund Razonable, MD, discusses cytomegalovirus (CMV) management strategies beyond primary prophylaxis in solid organ transplantation recipients including:

• CMV treatment goals 
• CMV treatment and monitoring recommendations
• Role of secondary prophylaxis
• Use of CMV cell–mediated immunity (CMI) monitoring for CMV relapse risk
• Use of CMV CMI for secondary prophylaxis 
• Proposed use of CMV CMI monitoring for secondary prophylaxis
• Incidence and outcomes with antiviral resistance 
• Risk factors for CMV resistance
• When to suspect antiviral resistance 
• Testing for antiviral resistance using genotypic assays
• Outcomes in patients with ganciclovir-resistant vs ganciclovir-susceptible virus
• Treatment recommendations for resistant/refractory CMV
• Efficacy and safety of maribavir vs investigator-assigned therapy for resistant/refractory CMV infections from the phase III SOLTICE study
• Treatment algorithm for resistant/refractory CMV 
• Adjunctive, investigational, and off-label treatment options for resistant/refractory CMV

Faculty:

Raymund Razonable, MD
Professor of Medicine
Program Director, Infectious Diseases Fellowship
Vice Chair, Division of Infectious Diseases
Mayo Clinic
Rochester, Minnesota 

Content based on a CME program supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.

Follow along with a downloadable slideset at: 
https://bit.ly/476v2wI

Link to full program: 
https://bit.ly/47lNK2K